Role of conventional oral antidiabetic drugs in management of type 2 diabetes mellitus
Abstract
Keywords
Full Text:
PDFReferences
American Diabetes Association. Statistics about diabetes. Data from the national diabetes statistics report, 2014.
American Diabetes Association. Economic costs of diabetes in the US in 2012. Dia Care. 2013;36:1033-46
Wilper AP, Woolhandler S, Lasser KE, McCormick D, Bor DH, Himmelstein DU. Hypertension, diabetes, and elevated cholesterol among insured and uninsured US adults. Health Aff (Millwood). 2009;28:1151-9.
American Diabetes Association; European association for the study of diabetes; International federation of clinical chemistry and laboratory; international diabetes federation medicine. consensus statement on the worldwide standardization of the HbA1C measurement. Diabetologia. 2007;50(10):2042-3.
American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endo Pract. 2007;13(1):1-68.
Ganz ML, Wintfeld NS, Li Q, Lee YC, Gatt E, Huang JC. Severe hypoglycemia rates and associated costs among type 2 diabetics starting basal insulin therapy in the United States. Curr Med Res Opin. 2014;30(10):1991-2000.
Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA, 2002;287:360-72.
TaplinCE, BarkerJM. Autoantibodies in type 1 diabetes. Autoimmunity. 2008;41:118.
Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet. 1974;2:1279-83.
Schatz D, Krischer J, Horne G. Islet cell antibodies predict insulin-dependent diabetes in United States school age children as powerfully as in unaffected relatives. J Clin Invest. 1994;93:2403-7.
Bolli G, de Feo P, Compagnucci P. Abnormal glucose counter-regulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes. 1983;32:134-41.
Moloney PJ, Coval M. Antigenicity of insulin: diabetes induced by specific antibodies. Biochem J. 1955;59:179-85.
Meier JJ, Ueberberg S, Korbas S, Schneider S. Diminished glucagon suppression after beta-cell reduction is due to impaired alpha-cell function rather than an expansion of alpha-cell mass. Am J Physiol Endocrinol Metab. 2011;300:E717-23.
Ferrannini E. The stunned beta cell: a brief history. Cell Metab. 2010;11:349-52.
Krentz A, Bailey C. Oral antidiabetic drugs- current role in type 2 diabetes mellitus. Drugs. 2005;65(3):385-411.
Miller RA, Chu Q, Xie J, Foretz M, Viollet B, BirnbaumMJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013;494:256-60.
Klip A, Leiter LA. Cellular mechanism of action of Metformin. Dia Care. 1990;13(6):696-704.
Bailey CJ. Metformin. N Engl J Med 1996;334(9):574-9.
UK Prospective Diabetes Study Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;52:837-53.
Nasri H. On the occasion of the world diabetes day 2013; Diabetes education and prevention; a nephrology point of view. J Ren Inj Prev. 2013;2:31-2.
Tertti K, Ekblad U, Vahlberg T, Rönnemaa T. Comparison of metformin and insulin in the treatment of gestational diabetes: A retrospective, case-control study. Rev Diabet Stud. 2008;5:95-101.
Kar P, Holt RI. The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes. Cardiovasc Drugs Ther. 2008;22(3):207-13.
Monami M, Lamanna C, Marchionni N. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;79(2):196-203.
Intestinal lipoprotein secretion: incretin-based physiology and pharmacology beyond glucose. Diabetes. 2015;64(7):2338-40.
Holst JJ. The physiology of glucagon-like peptide 1. Physiol. Rev. 2007;87(4):1409-39.
Lund A. Emerging GLP-1 receptor agonists. Expert Opin Emerg Drugs. 2011;16(4):607-18.
Butler PC. GLP-1-based therapy for diabetes: what you do not know can hurt you. Dia Care 2010;33:453-5.
Bjerre Knudsen L. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473-86.
Gier B. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97:121-31.
Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39-47.
Ahrén B. Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Dia Care. 2007;30(6):1344-50.
Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA. 2007;298:194-206.
Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153-65.
Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-705.
Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. Curr Dia Rep. 2006;6:194-201.
Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Dia Care. 2006;29:1963-72.
Babu A. Canagliflozin for the treatment of type 2 diabetes. Drugs Today. 2013;49:363-76.
Gurnell M, Savage DB, Chatterjee VK, O’Rahilly S. The metabolic syndrome: peroxisome proliferator-activated receptor gamma and its therapeutic modulation. J Clin Endocrinol Metab. 2003;88:2412-21.
Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes. 1994;43:1203-10.
Sotiropoulos KB, Clermont A, Yasuda Y. Adipose specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPAR𝛾 agonist’s effects on edema and weight gain. FASEB J 2006;20(8):1203-5.
Lago RM, Singh |PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370(9593):1129-36.
Ge R, Huang Y, Liang G, Li X. 11B-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development. Curr Med Chem. 2010;17:412-22.
Andrews RC, Rooyackers O, Walker BR. Effects of the 11beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone in insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab. 2003;88:285-91.
Henke BR, Sparks SM. Glycogen phosphorylase inhibitors. Mini Rev Med Chem. 2006;6:845-57.
Matschinsky FM, Porte D Jr. Glucokinase activators (GKAs) promise a new pharmacotherapy for diabetics. F1000. Med Rep. 2010;2:43.
Shah P, Vella A, Basu A. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000;85:4053-9.
Knop FK, Vilsbøll T, Hojberg PV. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007;56:1951-9.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA. 2007;12(298):1180-8.
Flynn DM, Smith AH, Treadway JL, Levy CB, Soeller WC, Boettner WA, et al. The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits. Cardiovasc Drugs Ther. 2005;19:337-46.
Mocanu MM, Maddock HL, Baxter GF, Lawrence CL, Standen NB, Yellon DM. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103:3111-6.
Letter: Clark MH, FDA, to Silberstein D, Squibb BM, dated November 1, 2006. Available at: http://www.fda.gov/cder/foi/appletter/2006/020357s030,021202s015ltr.pdf. Accessed August 13,2007.
Glucophage [prescribing information]. New York, NY; Bristol-Myers Squibb; 2006.
Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J. 2005;149:168-74.